Gabapentin and Toxic optic neuropathy - a phase IV clinical study of FDA data

Summary:

Toxic optic neuropathy is reported as a side effect among people who take Gabapentin (gabapentin), especially for people who are male, 30-39 old, also take Lubiprostone, and have Lung transplant rejection.

The phase IV clinical study analyzes which people have Toxic optic neuropathy when taking Gabapentin. It is created by eHealthMe based on reports of 313,421 people who have side effects when taking Gabapentin from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in peripheral neuropathy. eHealthMe is studying from 322,990 Gabapentin users. Check the latest studies of Gabapentin.

What is Toxic optic neuropathy?

Toxic optic neuropathy (optic nerve damage caused by toxic (harmful) substances) is found to be associated with 43 drugs and 107 conditions by eHealthMe. Check the latest studies of Toxic optic neuropathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

313,421 people reported to have side effects when taking Gabapentin.
Among them, 16 people (0.01%) have Toxic optic neuropathy.

Could Gabapentin cause Toxic optic neuropathy?

Among these 16 people:

What is the gender of people who have Toxic optic neuropathy when taking Gabapentin? *

female: 6.67 %
male: 93.33 %

What is the age of people who have Toxic optic neuropathy when taking Gabapentin? *

What are other drugs people take besides Gabapentin? *

What are other side effects people have besides Toxic optic neuropathy? *

Blindness: 5 people, 31.25%
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system): 4 people, 25.00%
Macular Degeneration (painless eye condition that leads to the gradual loss of central vision): 4 people, 25.00%
Transplant Rejection (a transplant material is not worked): 3 people, 18.75%
Overdose: 2 people, 12.50%
Drug Level Decreased: 2 people, 12.50%
Immunosuppressant Drug Level Increased: 2 people, 12.50%
Immunosuppressant Drug Level Decreased: 2 people, 12.50%
Vision Blurred: 1 person, 6.25%
Drug Level Increased: 1 person, 6.25%

What are the existing conditions these people have? *

Lung Transplant Rejection (failure of lung transplant): 7 people, 43.75%
Immunodeficiency Disorders: 2 people, 12.50%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 6.25%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 6.25%
Muscle Aches (muscle pain): 1 person, 6.25%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 6.25%
Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Toxic optic neuropathy?

- Check whether Toxic optic neuropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gabapentin:

Gabapentin (322,990 reports)

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Toxic optic neuropathy:

Toxic optic neuropathy (43 drugs)

Browse all the conditions that are associated with Toxic optic neuropathy:

Toxic optic neuropathy (107 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.